827318-97-8

Basic information

• Product Name: Danusertib
• Synonyms: danusertib;N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;PHA-739358;(R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide,PHA739358;Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-C)pyrazol-3-yl)-;Unii-m3X659D0fy;Danusertib(PHA-739358);PHA-739358(Danusertib)
• CAS NO: 827318-97-8
• Molecular Formula: C26H30N6O3
• Molecular Weight: 474.55
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Apis;Inhibitor
• Mol File: 827318-97-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 664.149 °C at 760 mmHg
• Flash Point: 355.465 °C
• Appearance: white powder
• Density: 1.322
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.70±0.20(Predicted)
• CAS DataBase Reference: Danusertib(CAS DataBase Reference)
• NIST Chemistry Reference: Danusertib(827318-97-8)
• EPA Substance Registry System: Danusertib(827318-97-8)

Safety Data

• Hazardous Substances Data: 827318-97-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 827318-97-8 differently. You can refer to the following data:
1. Danusertib is an Aurora kinase inhibitor, used to treat patients with chromic myeloid leukemia.
2. An Aurora kinase inhibitor, used to treat patients with chromic myeloid leukemia. It is a COVID19-related research product.

Biological Activity

danusertib (previously known as pha-739358), a 3-aminopyrazole derivative identified during the development of the pyrrolopyrazole sub-series, is a potent small-molecule inhibitor of aurora kinases family members with a dominant inhibition for aurora b kinase (abk). this pan-aurora kinases inhibitor is also able to inhibit several tyrosine kinases, including t315i mutant, ret, trk-a and fibroblast growth factor receptor-1 (fgfr-1), which are involved in multiple malignancies, such as chronic myelogenous leukemia (cml), acute lymphoblastic leukemia (all), thyroid prostate and breast carcinoma. thus, in many previous studies, danusertib exhibits remarkable antitumor activity in a number of different xengorafts, spontaneous, and transgenic animal tumor models with a favorable pharmacokinetic and safety profile.carpinelli p, ceruti r, giorgini ml, cappella p, gianellini l, croci v, degrassi a, texido g, rocchetti m, vianello p, rusconi l, storici p, zugnoni p, arrigoni c, soncini c, alli c, patton v, marsiglio a, ballinari d, pesenti e, fancelli d, moll j. pha-739358, a potent inhibitor of aurora kinases with a selecyive target inhibiton profile relevant to cancer. mol cancer ther 2007; 6(12 pt 1): 3158-3168

InChI:InChI=1/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1